Abstract
The article is dedicated to modern treatment of mucoviscidosis. The article covers issues of pathogenesis and emphasizes importance of mucociliary clearance and anatomic-physiological peculiarities of respiratory tract’s structure in childhood in the development of the disease. The article shows that efficient treatment of this disease requires an early beginning of pathogenetic treatment in combination with kinesitherapy. The article shows that the currently used drug – dornase alfa – has 3 key clinical effects – mucolytic, anti-inflammatory and antibacterial. Complex action of dornase alfa should be remembered; the treatment should be continued to prevent development of infectious complications typical for mucoviscidosis. The article also lists general rules of conducting inhalations and using dornase alfa in combination with kinesitherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
